Twist Bioscience (NASDAQ:TWST) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• Twist Bioscience received a "Sell (D-)" rating from Weiss Ratings, amidst a mix of other ratings from analysts, including a lowered price target from Evercore ISI.
• Shares of Twist Bioscience experienced a rise, trading at $34.11 with a market capitalization of $2.06 billion, while showing a 12-month range between $24.07 and $55.33.
• CEO Emily M. Leproust and another senior vice president sold portions of their shares on October 6th, indicating a decline in insider ownership as the company's stock fluctuates.

Twist Bioscience (NASDAQ:TWST - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities research analysts at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

TWST has been the subject of a number of other research reports. Evercore ISI lowered their price objective on shares of Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating for the company in a research report on Tuesday, October 7th. Cowen restated a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Finally, Barclays decreased their target price on shares of Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating for the company in a research report on Thursday, October 2nd. Nine equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $48.56.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST traded up $2.28 during trading on Friday, reaching $34.11. 1,600,362 shares of the company's stock traded hands, compared to its average volume of 1,956,458. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60. Twist Bioscience has a 12 month low of $24.07 and a 12 month high of $55.33. The company has a 50 day moving average of $28.43 and a 200-day moving average of $32.16. The stock has a market capitalization of $2.06 billion, a P/E ratio of -23.52 and a beta of 2.38.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The business had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities analysts expect that Twist Bioscience will post -2.12 EPS for the current year.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 31,348 shares of the company's stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $32.19, for a total value of $1,009,092.12. Following the completion of the transaction, the chief executive officer owned 601,212 shares in the company, valued at approximately $19,353,014.28. This represents a 4.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Paula Green sold 9,724 shares of the company's stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $32.19, for a total transaction of $313,015.56. Following the completion of the sale, the senior vice president directly owned 114,678 shares of the company's stock, valued at approximately $3,691,484.82. This represents a 7.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,368 shares of company stock worth $2,036,204 in the last quarter. 3.01% of the stock is currently owned by corporate insiders.

Institutional Trading of Twist Bioscience

A number of institutional investors have recently made changes to their positions in the stock. ARK Investment Management LLC lifted its stake in shares of Twist Bioscience by 2.5% in the 2nd quarter. ARK Investment Management LLC now owns 6,400,441 shares of the company's stock worth $235,472,000 after acquiring an additional 158,846 shares during the period. Vanguard Group Inc. lifted its stake in shares of Twist Bioscience by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company's stock worth $230,356,000 after acquiring an additional 60,276 shares during the period. William Blair Investment Management LLC lifted its stake in shares of Twist Bioscience by 2.6% in the 2nd quarter. William Blair Investment Management LLC now owns 3,906,604 shares of the company's stock worth $143,724,000 after acquiring an additional 99,737 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Twist Bioscience by 186.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock worth $95,883,000 after acquiring an additional 1,588,587 shares during the period. Finally, EdgePoint Investment Group Inc. lifted its stake in shares of Twist Bioscience by 114.3% in the 2nd quarter. EdgePoint Investment Group Inc. now owns 2,385,942 shares of the company's stock worth $87,779,000 after acquiring an additional 1,272,732 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.